[Intravitreal bevacizumab followed by focal laser for diffuse diabetic macular edema of recent progression. A clinical case].
METHODS
We report the case of a 48-year-old man with diffuse diabetic macular edema of recent progression treated with two consecutive intravitreal injections of bevacizumab followed by focal laser therapy, with good anatomic and functional response.


CONCLUSIONS
Diffuse diabetic macular edema is difficult to manage and frequently requires multiple therapies. We propose the use of bevacizumab as a strategy to reduce diffuse macular edema, facilitating the application of laser therapy.
Moreno-López
M
M
Servicio de Oftalmología, Hospital Ramón y Cajal, Madrid, España. mqmorenol@yahoo.es
Regueras
A
A
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018450:Disease Progression; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab